Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 4/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.69 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.69 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.69 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.69 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.69 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.69 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.69 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.69 |
| ▸ | MET | P08581 | 1/20 | 0.67 |
| ▸ | NQO2 | P16083 | 1/20 | 0.67 |
| ▸ | FECH | P22830 | 1/20 | 0.67 |
| ▸ | CLK3 | P49761 | 1/20 | 0.67 |
| ▸ | MMP1 | P03956 | 5/20 | 0.54 |
| ▸ | MMP2 | P08253 | 5/20 | 0.54 |
| ▸ | MMP9 | P14780 | 5/20 | 0.54 |
| ▸ | EGFR | P00533 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18437874 | 1.00 | PLK1 (0.69) | PLK1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL18437630 | 0.91 | PLK1 (0.67) | PLK1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL18437628 | 0.91 | PLK1 (0.67) | PLK1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL18438100 | 0.89 | PLK1 (0.70) | PLK1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL18437686 | 0.89 | PLK1 (0.70) | PLK1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL18437685 | 0.89 | PLK1 (0.70) | PLK1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL18437778 | 0.87 | PLK1 (0.69) | PLK1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL18480644 | 0.87 | PLK1 (0.69) | PLK1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL18437780 | 0.87 | PLK1 (0.69) | PLK1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL18438004 | 0.87 | PLK1 (0.69) | PLK1HDAC1HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10383831-B2 | 2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use | Temple University—Of the Commonwealth System of Higher Education (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180243239-A1 | 2,4,6-TRIALKOXYSTRYL ARYL SULFONES, SULFONAMIDES AND CARBOXAMIDES, AND METHODS OF PREPARATION AND USE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2018-08-30 | — | — | US | disclosed |
| WO-2017023912-A1 | 2,4,6-TRIALKOXYSTRYL ARYL SULFONES, SULFONAMIDES AND CARBOXAMIDES, AND METHODS OF PREPARATION AND USE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10383831-B2 | 2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use | CCNY, STS, ARSA | PLK1 4102/4885HDAC1 1074/4885HDAC3 875/4885 |
| US-20180243239-A1 | 2,4,6-TRIALKOXYSTRYL ARYL SULFONES, SULFONAMIDES AND CARBOXAMIDES, AND METHODS OF PREPARATION AND USE | CCNY, STS, ARSA | PLK1 4102/4885HDAC1 1074/4885HDAC3 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.